|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||83.15 - 84.24|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.27|
|Dividend & Yield||2.72 (3.22%)|
|1y Target Est||N/A|
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including one oil name.
Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.
Cryoport (CYRX) reported Q2 2017 financial results. Results continue to impress as revenue set another new high, extending that streak to 11 straight quarters. Consistent increases in the number of clinical trials that the company supports remains the major catalyst to the topline growth. That metric (i.e. Q2 revenue, at $2.9M, was up 52% yoy and inline with our $2.9M estimate. It is also a new record and up almost 8% sequentially from Q1 (the prior best). This is the fifth consecutive quarter in which revenue came in slightly better and operating loss much better than our respective estimates. The $60k revenue difference in Q2 compared to our estimate relates to $36k beat ($2.22M A vs. $2.19M) in biopharma and $25k ($426k A vs. $401k E) beat in reproductive medicine, partially offset by $20k miss ($263k A vs. $283k E) in animal health.